Summary
- Poliomyelitis: enteroviral infection with faecal-oral transmission
- There are three related polioviruses, but no immunological cross-protection
- Often asymptomatic infections
- Sometimes flu-like syndrome with muscle pain and fever
- In a minority of patients flaccid paralysis with sensation intact follows
- Vaccination is very effective as prevention
- Anno 2016 the Global Polio Eradication Programme has not yet achieved final goal
- Emergence of vaccine-derived (reverse mutation) pathogenic viral strains
General
Poliomyelitis is a disease caused by a picornavirus (family enteroviruses). There are 3 different polioviruses, i.e. types 1, 2 and 3. They do not exhibit immunological cross-reactions. Chimpanzees, Rhesus monkeys and cynomolgus monkeys (syn. Macaca fascicularis) can be infected orally and suffer paralysis as a result, but in practice man is the only reservoir. Chronic latent carriers are very rare, but healthy and immune-compromised long-term virus shedders were identified, excreting poliovirus for more than 20 years. The epidemiological importance of these people is not yet known. The virus does not survive in the wild –ex. sewage and surface water- for more than a few months, and then only under conditions of low temperatures and high humidity.
Historical Note
Poliomyelitis has been known since ancient times. An Egyptian carving from 1580 BC shows typical sequalae of poliomyelitis. At present, it is in the Carlsberg Glyptothek Museum in Copenhagen, Danmark. A 3,500-year-old Egyptian limestone funeral stela represents a man called Roma, giving offerings to the Goddess Astarte. He was a doorkeeper of the Eighteenth or Nineteenth Dynasty. He is portrayed with a wasted and shortened leg accompanied by an equinus deformity of the foot. The most likely diagnosis is that these are sequelae from poliomyelitis acquired in childhood. The person appears with a stick which could be used as a crutch. His disability had clearly not prevented his attaining high office, marrying and having at least one child.
In 1916 there was a polio epidemic in the USA with more than 10,000 cases. It was noticeable that most victims with paralysis were found among those groups of the population that observed the greatest possible hygiene precautions. It was referred to as a disease of cleanliness. At that time the washing of the whole body (rather than just the face and hands) and the installation of bathrooms in the houses of wealthy citizens was greatly on the increase. The improved hygiene ensured that the infection did not develop at a very youthful age. The disease follows a more serious course when it occurs at a more advanced age. Under poor hygiene conditions, children are infected at a very young age, a small proportion of whom will develop paralysis (“infantile paralysis”). In 1952-53 Europe experienced a very severe epidemic. North America also was not spared, with 55,000 cases in 1953.
In the early 1950s, Jonas Salk developed the first formalin-inactivated injectable vaccine. This became available in the USA from April 1955. This was then followed in 1960 by the oral vaccine developed by the Polish clinician Albert Sabin. Important work was also undertaken by Dr Hilary Koprowski, head of the Wistar Institute in Philadelphia, in relation to an experimental oral poliomyelitis vaccine (“CHAT” vaccine). The incidence of the disease has declined very markedly since the introduction of vaccination. Poliomyelitis at present still exists in developing countries, particularly in young children. Because the only reservoir is the human being with no persisting infection and because of the efficiency of vaccination, it is an eradicable disease. Though rare persistent carriers exist mostly due to an underlying immune defect. In May 1988, the WHO adopted a resolution to eliminate poliomyelitis (“Global Polio Eradication Initiative”).
The hope that it would be possible to achieve the total eradication of poliomyelitis by the turn of the century has not become a reality. As long as a single person remains carrier of poliovirus, children in all countries are at risk of contracting the disease. The poliovirus can easily be imported into a polio-free country and can spread rapidly amongst unimmunized populations. In 1988, 350,000 cases (1000 children per day) were officially reported in 125 countries. The number is steadily declining. In 1996, the figure was still 4,000 and there were less than 2,000 registered cases in 2002. The last countries in which wild type poliovirus type 2 occurred were Afghanistan in 1997, Nigeria in 1998 and India in 1999. The last known reservoirs of type 2 were in Bihar, Uttar Pradesh and West Bengal. In 2001 the WHO reported that wild type poliovirus type 2 had been eradicated around the world.
In late 2005 however, vaccine-derived polio virus type 2 reappeared in Nigeria. It was not wild type virus which reappeared but a pathogenic reverse mutant from oral polio vaccine. The emergence of serotype 2 circulating vaccine-derived poliovirus (cVDPV) has complicated the epidemiology of polio. The type 2 component in trivalent OPV accounts for more than 90% of all cVDPV cases. By 2020, 24 cVDPV outbreaks have occurred in 21 countries, resulting in more than 750 cases of paralytic polio. The biggest risk factor for cVDPV emergence is low vaccination coverage. It will take many months for a cVDPV to emerge and cause and to cause an outbreak. These outbreak can cVDPV to become endemic and to spread further in under vaccinated communities and even to other countries.
Of note: cVDPV (circulating vaccine-derived polio virus) is not the same as VAPP (vaccine-associated paralytic polio). The latter is caused by a strain of poliovirus that reverts to a neurovirulent variant following OPV administration. This causes a paralysis clinically indistinguishable from poliomyelitis caused by the wild type poliovirus. VAPP occurs in recently vaccinated patients and sometimes in close contacts of recently vaccinated persons (contact VAPP). The weakened virus in VAPP does not cause outbreaks. It is estimated to occur in 1 out of 2.34 million administered first doses of OPV.

A recent successful event in the polio eradication programme was the declaration of a world free of wild type poliovirus type 3 in October 2019. Since 2012, the only wild type polio virus is type I and today it is only circulating in Afghanistan and Pakistan. In 2019 176 WPV1 infections were diagnosed in Afghanistan and Pakistan and 365 cases of cVDPV were diagnosed worldwide of which 40 in Afghanistan and Pakistan and 325 in non-endemic countries, mainly in sub-Saharan Africa. The militant Taliban claim that oral polio vaccination is a Western plot to sterilise Muslim children shows that success can be hampered if the 2019 numbers are compared with 2017: that year only 22 WPV1 cases were reported.
Pathophysiology

Transmission is faecal-oral by ingestion of contaminated food or water. The viruses proliferate in the intestinal mucosa. The virus can still be found in the faeces up to a few months after infection. The virus does not cause diarrhoea. During the acute phase, it is also found in the throat. After passing into the body from the intestinal tract, the virus becomes localized in various tissues, such as the lymph nodes. On the cell membrane, the virus attaches itself to a specific protein: human poliovirus receptor (CD155). This protein belongs to the immunoglobulin superfamily and occurs in several tissues (brain, spinal cord, kidneys, heart, etc.). However, some cells that express the receptor appear not to suffer any adverse effect, probably because one of the subsequent stages in the intracellular replication of the poliovirus is blocked.
In a small percentage of cases, dissemination occurs to the central nervous system (it is “neurotropic”) where it can cause an non-paralytic aseptic meningitis. In about 1 percent of infections, the virus spreads to the grey matter in the ventral spinal cord (“polios” = grey, “myelon” = marrow) where the motor neurons are found. These are nerve cells that transmit impulses to the muscles. These cells become damaged or destroyed. Damage often occurs at other sites, but is usually less pronounced (medulla, cerebellar vermis, midbrain, thalamus, cerebral motor cortex).
Clinical aspects

The incubation period is 9 to 12 days (rare extremes 3-35 days). The infection can follow a variety of courses: asymptomatic, flu-like syndrome, aseptic meningitis or paralytic. The most common is an asymptomatic infection (95%). Some people will develop a short-lasting flu-like syndrome with slight muscle pain. In a small minority of cases (1%) meningitis occurs after this phase of minor signs and symptoms. Fever and muscle weakness can occur, initially sometimes with severe muscle pain. Highly characteristic is the fact that the muscle pain improves on movement. The reason is unclear. 0.1% Of the total number of those infected will subsequently progress rapidly to paralysis, sometimes within a few hours: “morning paralysis”. This is an asymmetrical, flaccid (no tendon reflexes) and often ascending paralysis (exacerbation over a few days). Sensation is not affected. Sometimes the lesions may be localized at a higher level from the onset. Bulbar involvement (10% of the total number of those paralyzed) damages cranial motor nerves such as the glossopharyngeal nerve (9th cranial nerve, palate, swallowing problems), the vagal nerve (10th cranial nerve, including the recurrent laryngeal nerve) and the facial nerve (7th cranial nerve). Occasionally the ocular muscle nerves – the 3rd, 4th and/or 6th cranial nerves – are involved. Hypoxia can occur as a result of involvement of the diaphragm and intercostal muscles. Even though the virus may affect muscles on both body sides, the paralysis is usually asymmetrical. Cerebrospinal fluid contains an increased number of lymphocytes. Recovery can take months, in the course of which marked hypotrophy of the muscles occurs. Mortality during the acute disease can reach 10% due to respiratory paralysis. The sequelae of spinal polio are often permanent if the affected nerve cells are completely destroyed leading to severe disability in a quarter of patients and mild disability in another quarter. In half the patients with spinal polio, cells are not completely destroyed and full recovery will take place with maximum possible improvement occurring within 6 months.
Bulbar versus pseudobulbar paralysis
Bulbar paralysis is caused by injury to the lower motor neurons (motor nuclei of the throat muscles), for example due to poliomyelitis or Guillain-Barré syndrome. Speech is nasal and the tongue is flaccid, atrophic and exhibits fasciculations. The masseter reflex is normal or absent. In pseudobulbar paralysis, there is damage to the higher motor neurons. Speech is monotonous and contains many high tones: spastic dysarthria (“Donald Duck” speech). The tongue is spastic and the masseter reflex increased. There is no atrophy of the tongue.
Dysphasia versus dysarthria
In the case of dysphasia, speech is abnormal in content, usually as a result of a cerebrovascular accident. The disorder may be motor-related in the event of injury to the posterior-interior part of the dominant frontal lobe (Broca aphasia: the patient recognises an object but cannot say its name) or sensory as a result of damage to the temporal lobe (Wernicke aphasia: the patient does not understand the meaning of words).
In dysarthria there are difficulties of articulation, but the content of the speech is correct. Injuries to the 9th, 10th and 12th cranial nerves can result in dysarthria, dysphagia and nasal regurgitation.
Post-poliomyelitis syndrome
In some patients, progressive muscle weakness recurs several years after acute paralytic poliomyelitis in the muscle groups involved in the previous episode. Rapid fatigability, swallowing disorders, respiratory difficulties, muscle atrophy, discomfort and pain in muscles and joints can occur. This post-poliomyelitis syndrome affects one in three people who suffered paralytic poliomyelitis forty or fifty years earlier. It is apparently not caused by reactivation of dormant polioviruses. The exact aetiology is unknown. One hypothesis is that the symptoms are due to natural progressive deterioration of the remaining motor neurons. An as of yet unelucidated immunological mechanism might play a role. There is no specific therapy apart from muscle-strengthening exercises. Evidently, further study is necessary to understand this condition better.
Diagnosis
Most victims are children less than 5 years old. The diagnosis is clinical. A predominantly asymmetrical flaccid paralysis of sudden onset with decreased or absent tendon reflexes with normal sensation, normal level of consciousness and preceded by muscle pain is suggestive. Often there is fever and meningeal irritation. Routine laboratory tests show few abnormalities. Lumbar puncture suggests viral meningitis (lymphocytic pleocytosis). Virus isolation may be undertaken by throat culture and/or faecal culture. Serological tests with type-specific IgM on serum or on liquor can be performed but, like viral culture, are rarely available. WHO installed worldwide equipped labs for investigation of acute flaccid paralysis cases (Collaborating Center for Reference and Research on Poliomyelitis). Confirmed cases are usually thoroughly examined with PCR to establish whether it involves a “wild type” virus or whether it is a reverse mutation of a vaccine strain. For every diagnosed wild type poliovirus infection, about 2000-3000 asymptomatic carriers exist, underlining the importance to determine the source of the ‘outbreak’.
Initial differential diagnosis includes:
- Guillain-Barré syndrome or acute inflammatory demyelinating polyneuropathy is characterized by an ascending symmetrical paralysis with sensory involvement (reduced sensation and paresthesia). A form predominantly affecting the cranial nerves also exists (Miller- Fisher syndrome). Respiration becomes affected in the late stages. Determination of the vital capacity of the lungs is important. In Guillain-Barré syndrome, the cerebrospinal fluid is very typical: large quantities of protein and only a slight increase in cell count. In early stages, the CSF can still be normal. In such cases, repeated lumbar puncture is essential one week later. In the case of poliomyelitis, there is pleocytosis (large numbers of lymphocytes) in the cerebrospinal fluid and a slight elevation of protein. With poliomyelitis there is usually no progression of the paralysis after the 4th day, in contrast to Guillain-Barré.
- Tick paralysis: some ticks secrete a paralytic substance in their saliva. This causes an ascending symmetrical paralysis with paresthesia, often around the mouth. The paralysis gradually increases over 5 to 6 days. Removal of the tick produces a dramatic improvement within a few hours or days. There is no fever or pain.
- Paralytic rabies: previous history of infected bite (sometimes the victim is unaware of the bite: role of bats in South America). Ascending flaccid paralysis with moderate sensory disorders and with a fatal outcome.
- Acute transverse myelitis: transverse lesion with bilateral sensory and motor disorders below a certain level (spinal cord segment) with back pain and flaccid paralysis initially, and subsequently spastic paralysis and major sphincter disorders. The cerebrospinal fluid often exhibits pleocytosis and a raised protein content. Consideration should also be given to trauma, herniated disk, acute schistosomiasis, compression by a spinal abscess or tumour (possibly acute symptoms from bleeding in a tumour), complications of brucellosis and Pott’s disease.
- Diphtheria: Caused by toxins secreted by Corynebacterium diphtheriae. Aerogenic transmission. Incubation period 2 to 5 days. Mostly throat infection, often with pseudomembranes, dysphagia, airways obstruction, markedly enlarged cervical lymph nodes and leukocytosis. This is followed by heart failure (myocarditis) around the 2nd week and sometimes peripheral paralysis (neuritis) around the 3rd to 6th weeks. The nerve damage often occurs first in the throat, palate and the ocular muscles and may subsequently become generalised. Sometimes the infection is localised in the nose or skin, which then tends to follow a less aggressive course. Untreated patients remain infectious for 2 to 3 weeks. Treatment consists of antibiotics [(neo)macrolides or penicillins] and diphtheria antitoxin.
- Buckthorn poisoning. The clinical picture which follows ingestion of the berries of buckthorn (Karwinskia humboldtiana and K. calderoni) resembles poliomyelitis and Guillain-Barré syndrome. The neurotoxic effects of this plant are well known in Mexico and Central America (Nicaragua!) and consist of an ascending symmetric flaccid paralysis, often leading to bulbar paralysis and death.
- Botulism: Intoxication by neurotoxins (type A, B or E) secreted by a Gram-positive anaerobic bacterium Clostridium botulinum. The toxins (zinc endopeptidases, cf. tetanus) bind presynaptically, interfere with the neurotransmitter vesicles and thus prevent the release of acetylcholine. Botulinum toxins B, D, F and G cleave synaptobrevin. Botulinum toxins A and E cleave SNAP-25 and botulinum toxin C1 cleaves syntaxin (all vesicle-associated proteins). The organism (or heat-resistant spore) can be found in a wound, the colon or in food. The role of food is reflected in the name of the disease: “Botulus” = sausage, after an incident in the 18th century in southern Germany. Bacteria can proliferate in anaerobic conditions and secrete toxins. If this happens and people eat contaminated food, disease will follow. After 12-36 hours a bilateral symmetrical and descending flaccid paralysis occurs with hypotension, dry mouth, ptosis, diplopia with dilated pupils and no light reflex, constipation and often distended abdomen (ileus) and urinary retention. Bulbar paresis with dysarthria and dysphagia may be particularly apparent and result in aspiration pneumonia. Respiratory paralysis can follow. Tendon reflexes are impaired or absent. There is normal sensation, no fever, normal consciousness, normal cerebrospinal fluid. There will be normal base line laboratory test results. Wound botulism causes no intestinal symptoms. A rapid improvement of the symptoms is obtained within a few hours with anti-ABE antitoxin (horse serum; 1 ampoule IV and 1 IM, repeated if no improvement after 2-4 hours), but complete recovery is usually very slow (weeks to months). It is a rare condition and it is difficult to diagnose. Specific EMG patterns can be detected (including a reduction in muscle action potentials at low frequency stimulation and post-tetanic potentiation, i.e. increase in muscle action potentials after high frequency stimulation or maximum voluntary muscle contraction for 30-60 seconds). An EMG as well as specific bacterial cultures and bioassays in mice to detect toxins are in general not available in developing countries. Even in well-equipped medical centres, confirmation of botulism is difficult. Botulinum toxin is used in medicine in a number of different indications, such as for the control of spasms in superficial muscles (e.g. around the eye, blepharospasms), in focal dystonia, in chronic anal fissures, in achalasia and Chagas’ disease and even in axillary hyperhydrosis. In this last case, injections of botulinum toxin A are used. The toxin blocks the release of acetylcholine at the neuromuscular junction but also at the cholinergic autonomic nerve endings (reduced sweat production as a result).
- Myasthenia gravis and Lambert-Eaton myasthenia syndrome (e.g. in bronchial carcinoma) can also cause paralysis of the ocular muscles, ptosis, facial muscle weakness and swallowing difficulties, but the course is slower. If available, an EMG and an edrophonium test (Tensilon®) are useful.
- Viral meningitis. If the clinical presentation is that of acute viral meningitis, mumps, Coxsackie A7, Enterovirus 71 and echoviruses should be considered in addition to infection with poliovirus. Naturally this can only be established by a sophisticated laboratory.
- Enterovirus 71 deserves some additional comment. It was first isolated in a cell culture from a child with encephalitis in California in 1969. It is easily transmissible, which is important for contact persons within a family. The virus can be isolated from stools. There were large epidemics in Eastern Europe in 1975 and 1978 and in Southeast Asia (Malaysia, Singapore, Taiwan) between 1997 and 2000. In most outbreaks hand, foot and mouth disease has been the dominant clinical presentation, although herpangina, interstitial pneumonia, myocarditis, intrauterine infection and neonatal hepatic necrosis occur sporadically. The virus is also neurotropic. In contrast to other enteroviruses, it can invade the ventral brainstem, cerebellum and spinal cord. This results in a spectrum of serious neurological syndromes, ranging from acute flaccid paralysis of one or more extremities, to cranial nerve paresis, tremors, myoclonus and ataxia. Acute pulmonary oedema is thought to result from the destruction of medullary respiratory and vasomotor centres, leading to central sympathetic activation with severe systemic vasoconstriction and pulmonary vascular overload. The nervous damage is due to direct invasion of the neurons by the virus, as well hypoxia. Children who had encephalitis and cardiopulmonary failure have a high risk of poor neurodevelopment and cognitive outcome. Nowadays epidemic paralytic disease is more likely to be caused by EV-71 than by polioviruses.
- Acute beriberi (thiamine deficiency). Develops more slowly with muscle weakness and often also heart failure. Good response to thiamine. See chapter on nutrient deficiencies.
Differential diagnosis of Acute Flaccid paralysis, summary
- Polio : CSF, lymphocytic meningitis, PCR, viral culture
- West Nile Fever virus polio–like : CSF, lymphocytic meningitis, serology, PCR, viral culture
- Enterovirus 71 polio-like : CSF, lymphocytic meningitis, PCR, viral culture
- Guillain-Barré / Fischer : CSF, protein-cellular dissociation
- Diphtheria : inflammation throat or nose, LN, cardiomyopathy
- Botulism : dry mouth, constipation, blurred vision, mydriasis, toxin assay
- Rabies, paralytic : CSF variable, consciousness variable, agitation, relentless progression till death, IF, PCR
- Myasthenia crisis, Eaton : Tensilon (edrophonium) or neostigmine test, EMG, anti-acetylcholine-receptor antibodies
- Beriberi : cardiac, subacute, poor nutrition, vomiting, ethanol, thiaminases
- Periodic paralysis : recurrent, induced by effort or sugars, K+ concentrations variable
- Hypophosphatemia : alcoholism or rapid feeding after starvation, TPN
- Tick paralysis : specific hard tick present, better after removal
- Neurotoxic snake : history, ptosis, dysphagia, bite wound
- Organophosphates : hypersalivation, cramps, diarrhoea, sweat, miosis, wheezing, bradycardia
- Shellfish poisoning (PSP, NSP) : ingestion shellfish, paresthesia, diarrhoea, ataxia, mydriasis
- Buckthorn poisoning : ingestion Karwinskia berries, New World
- Curare poisoning (medication) : peracute, only parenteral, New World, consciousness OK
- Fugu poisoning (TTX = tetrodotoxin) : ingestion fish, Asia; paresthesiae lips, peracute paralysis, consciousness OK
- TTX, other source : e.g. bite of blue-ringed octopus, see fugu poisoning
- Thallium poisoning : gastro-intestinal, painful polyneuritis (esp hands and feet), diplopia
Treatment
There is no specific treatment for poliomyelitis. Symptomatic and supportive measures are necessary. Bed rest is compulsory at the beginning of the disease as physical activity may aggravate the nerve damage. Moist heat packs relieve the muscle pain. Attention should be paid to the possibility of urinary retention as a result of bladder paralysis. Physiotherapy should be instituted 3 to 4 days after regression of the fever and if there is no further progression of the paralysis. Physiotherapy does not prevent the muscular atrophy that occurs as a result of denervation (destruction of the motor neurons). It does, however, maintain the muscles in good state for the few regenerating neurons. In 1927, Philip Drinker and Louis Agassiz Shaw Jr invented the iron lung at the Harvard School of Public Health. This is a respirator that allowed care for patients with paralysis of the respiratory muscles. It allowed for longer survival of certain patients, but also led to dramatic situations, where paralyzed people had to remain immobile inside the respirator for the rest of their lives.
Prevention
General
In the first half of the 20th century, poliomyelitis was a major problem in the West. The development of vaccines had a dramatic effect in a very short space of time. In many countries it has proved possible to eliminate poliomyelitis by means of a routine vaccination program. Within the space of a generation the disease has virtually disappeared in the developed countries. In some countries where poliomyelitis still occurs, annual national vaccination days are held in addition to the usual vaccination programs. In 1988, the Global Polio Eradication Initiative was launched and is led by 5 organizations: the WHO, the United States Centers for Disease Control and Prevention, the UN Children’s Fund, Rotary International and the Bill and Melinda Gates Foundations. Four pillars form the global eradication program:
- Routine infant vaccination
- Supplementary immunization activities in at-risk middle and low-income countries: door to door campaigns; eg a national campaign targeting all <5 years without regard to prior OPV immunization status
- Surveillance for acute flaccid paralysis (AFP)
- Mop-up campaigns: if a poliomyelitis patient or circulation of wild type virus of cVDPV is found, house-to house vaccination (“mopping-up” vaccination) is conducted over a large area.
As poliomyelitis is becoming increasingly rare, the importance of good surveillance is increasing. Patients with acute flaccid paralysis form the basis for the detection of “possible poliomyelitis”. Acute flaccid paralysis surveillance is the gold standard for surveillance in the polio eradication initiative. Cases of acute flaccid paralysis (AFP) must be officially reported. It may be assumed that every year in a population approximately 1/100,000 persons under 15 years of age will develop an acute flaccid paralysis (non-poliomyelitis). Where possible a stool specimen should be obtained for virus isolation in a regional Global Polio Laboratory Network laboratory. On top of AFP investigation, environmental surveillance sampling sewage effluents in high-risk areas complements AFP surveillance. Organisms that are found here (e.g. mutated vaccine strains) can be tested for neurovirulence in transgenic mice that are carriers of the human poliovirus receptor. The rationale for environment surveillance is based on the characteristic poliovirus excretion pattern. Infected individuals excrete poliovirus in faeces for periods up to several weeks, whether or not they are symptomatic. Occasionally very-long-term excretors will be encountered. As fewer AFP cases are to be expected, environmental surveillance may become more important to ensure early response, even before clinical cases re-occur.
In 1995, the “Global Commission for the Certification of the Eradication of Poliomyelitis” was established. This commission defined the principles, criteria and the process by which certification is to take place. All countries have to be able to show that they have stopped circulation of wild type virus. Certification, cannot be granted in less than three years from the last report of poliovirus. Each country should set up a national certification commission which should collect the necessary documentation. The national commission is not authorized to declare its own country poliomyelitis-free.
Vaccines
There are two types of vaccine:
Salk vaccine
The injectable Salk vaccine (1955) or IPV (Inactivated Polio Vaccine) can be administered IM or SC and has the advantage of being heat-stable, which is important under field conditions. It can also be given to immune depressed patients. It is more expensive than the Sabin vaccine. These vaccines protect a person against paralytic poliomyelitis but will not combat an asymptomatic infection in the intestinal tract. Vaccinees are still able to pass on the wild type virus to their environment. With the killed vaccine, no reverse mutations can occur. In most high-resource countries, IPV is integrated in the routine childhood vaccination programme.
Sabin vaccine
The oral Sabin vaccine (1960, OPV = oral polio vaccine) contains live attenuated viruses. It should be stored in a refrigerator. It is very efficient and cheap. It has the enormous advantage of being able to be administered without a syringe. If there is an intestinal infection (diarrhoea) during the vaccination, the vaccine has less chance of success. The first dose may be given immediately after birth. This is then followed by three doses at intervals of one to two months. A booster at the age of 18 months and 5 years is indicated. A return to neurovirulence is possible in case of specific reverse mutations. After vaccination with Sabin vaccine, the viruses can be excreted for a while. As an anecdote, poliomyelitis virus was isolated from the preflight stools of the Apollo 11 crewmen after the crewmen had been given poliomyelitis boosters.
Risks of vaccination vs non-vaccination
Questions are raised about the putative risks of poliomyelitis vaccination. In the 1950s there was the so-called “Cutter” incident (named after the Cutter laboratory). Children who received the supposedly inactivated vaccine subsequently developed the disease. This was due to a problem in the filtration process in the preparation of the vaccine. Aggregates which still contained pathogenic virus were not inactivated by the formalin and were not filtered out. This problem has obviously now long been corrected.
Between 1957 and 1960 the oral “CHAT” vaccine was used, particularly in Central Africa. The developer of this vaccine was accused of having used contaminated chimpanzee kidneys for this vaccine and therefore of having started the AIDS epidemic. This however has never been formally confirmed and this hypothesis has been rejected. Strains that were preserved from that time have been studied for the presence of HIV and all found to be negative.
The live viruses in the Sabin vaccine differ from the pathogenic viruses through a small number of mutations. Occasionally reverse mutations occur, as a result of which a vaccine virus can recover its pathogenicity (“vaccine derived polio viruses”).
Trivalent oral polio vaccine is highly protective against cVDPV. The only way to remove the risk of future similar mutations and clinical disease is switching to the less effective and more expensive dead injectable vaccine (estimated cost/dose for oral vaccine 0,15 US$ versus 3 US$ for injectable vaccine).
The prospects for eradication are goodbut setbacks do occur. In the autumn of 2003, there was a dramatic increase in poliomyelitis cases in Kano, Nigeria. Early November 2003, there were already 217 cases on a global total of 491. Vaccination had been stopped due to false rumours, fear and mistrust between the Muslim population and the government. This created a very dangerous situation, even threatening the accomplishments of the global eradication campaign. Over a year time, the virus spread far and wide to 20 different countries, from countries bordering Nigeria to even Indonesia. As an example, Somalia reported 73 cases in December 2005, after a three year period where not a single case was detected. Later it became clear that a small number of cases in Nigeria were due to the spread of a mutated vaccine strain. The financial price to quell this outbreak was very high, but we have to be prepared to go all the way to eradicate this disease from our planet.
Details on the Polio Eradication and Endgame Strategic Plan can be found at: http://polioeradication.org/who-we-are/
Switch from tOPV to bOPV and the future of OPV
Wild type 2 poliovirus disappeared in 1999. Nearly all vaccine-derived polioviruses in circulation are of type 2. Administration of the trivalent oral polio vaccine (tOPV, containing the 3 living vaccine strains) led mainly to an immune response against type 2. In April 2016a new bivalent oral poliovaccine (bOPV) has replace tOPV in all OPV-using countries, which will decrease cVDPV cases and VAPP cases due to type 2 poliovirus. The main reason to continue using the oral living vaccine is cost.
Given the WPV1 and WPV3 eradication, the use of all OPV in routine immunizations should be stopped and all countries will rely on IPV alone to prevent poliovirus after OPV withdrawal. As an intermediate step, high-risk countries can give ≥1 IPV dose in the routine immunization programme on top of the bOPV immunization, to maintain immunity levels to type 2 polio.
At the same time stockpiles of monovalent OPV type 2 are maintained to respond to future cVDPV2 outbreaks. Of course, the use of mOPV2 in response tot VDPV2 outbreaks increases the risk of seeding new VDPV2 outbreaks.
Prevention, comparison of vaccines
Table: Advantages and disadvantages of dead and live attenuated poliomyelitis vaccine
Dead vaccine (Salk) | Live vaccine (Sabin) |
Antibodies in the blood | Antibodies in the intestinal tract and blood |
Since there is no immunity in the intestinal tract, wild type virus can still be transmitted faecal-orally | Vaccine virus can spread to the family: beneficial for immunity. Sometimes transmission of virulent mutant. |
No mutations towards new virulence possible | Vaccine virus can mutate to neurovirulent type. |
Use permitted in immune deficiency | Possibly dangerous for immune deficient subjects |
Injection necessary | Oral administration |
Booster vaccinations necessary for long-term immunity Higher seroconversion rates than OPV in low-income settings where enteric pathogens/pathology reduces the OPV efficacy | Immunity for life |
Future
If poliomyelitis is successfully eradicated in the early 21st century, no wild type virus will then be present anywhere on the planet (except possibly for a few stocks in protected laboratories). However, Sabin strains can revert to the wild type form. Will the oral poliomyelitis vaccine ultimately have to be destroyed? For how much longer should the injectable, dead vaccine be used and/or kept? Will silent long-term excretors start an epidemic decades after stopping vaccination? Some immunocompromised people excrete wild type or vaccine-type poliovirus for years (possible for life?). As long as this situation exists, it cannot be stated that the battle against polio has been won.